Can Wegovy Move The Needle On NZ’s Obesity Crisis, Or Simply Treat Its Symptoms?

Trafford, Auckland University of Technology Even before receiving public funding, Wegovy has drawn much media attention in New Zealand for the dramatic difference it can make for weight loss.

But with its rise in popularity has come debate about what these next-generation drugs really mean for a worsening obesity crisis and its driving causes.

Last month, New Zealand’s drug-funding agency Pharmac added Wegovy to its list of medicines suitable for future public funding.

If that happens – and it could quickly – the drug would initially be targeted at people with severe obesity, or who are overweight with related health conditions.

Right now, the drug’s prescription costs – upwards of NZD$400 per month – places it beyond the reach of many New Zealanders, particularly those disproportionately affected by obesity.

This has strengthened arguments that public funding could improve equity while reducing long-term health-care All the while, New Zealand continues to report some of the developed world’s highest obesity rates.

Around one in three adults and one in eight children are today classified as obese, while roughly two thirds of adults are either overweight or That may make the prospect of public funding all the more attractive for the country and its health system.

But it should also be asked: can these drugs really be expected to tip the scales against an epidemic rooted in complex social and environmental Why we’re hearing about Wegovy works through semaglutide, a drug that helps regulate appetite and blood sugar, making people feel fuller for Clinical trials have shown that, when the drug is taken in tandem with lifestyle change, effects can be striking.

In one landmark study, participants lost around 15% of their body weight over 68 weeks, which was far more than those who instead took a placebo.

For some people, such weight-loss can be transformative – reducing the risk of diabetes, cardiovascular disease and other long-term conditions.

Still, the drug has drawbacks.

People generally need to keep taking it to maintain weight loss, with many....